CD82 and cancer: Its higher expression predicts a better prognosis,72–74 whereas reduced expression of KAI1 has been widely correlated with an aggressive cancer in several cancer types, including pancreatic, hepatocellular, bladder, breast and non-small-cell lung cancers.73,75,76